Accepted wisdom holds that high compliance is essential for a screening programme to be successful.
Indeed, a reason that the national breast screening programme is not routinely offered to women aged 65 or more is on the grounds of predicted poor compliance by older women.
Increasing compliance is often associated with increased costs.
These costs represent a lost opportunity for screening alternative target populations.
We question the need for screening programmes to achieve high compliance, and we argue that a screening programme can be efficient with very low levels of compliance.
Mots-clés Pascal : Glande mammaire pathologie, Economie santé, Tumeur maligne, Glande mammaire, Dépistage, Homme, Analyse avantage coût
Mots-clés Pascal anglais : Mammary gland diseases, Health economy, Malignant tumor, Mammary gland, Medical screening, Human, Cost benefit analysis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0166547
Code Inist : 002B20E02. Création : 199406.